Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates

被引:8
作者
Kanjer, Ksenija [1 ]
Tatic, Svetislav [2 ]
Neskovic-Konstantinovic, Zora [3 ]
Abu Rabi, Zaki [1 ]
Nikolic-Vukosavljevic, Dragica [1 ]
机构
[1] Inst Oncol & Radiol Serbia, Dept Expt Oncol, Belgrade, Serbia
[2] Univ Belgrade, Sch Med, Inst Pathol, Belgrade, Serbia
[3] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade, Serbia
关键词
Breast cancer; Primary chemotherapy; Ki-67; AI; Growth index; PATHOLOGICAL COMPLETE RESPONSE; TOPOISOMERASE-II-ALPHA; NEOADJUVANT CHEMOTHERAPY; BIOLOGICAL MARKERS; PREDICTIVE MARKERS; PROGNOSTIC VALUE; KI-67; PROLIFERATION; CLINICAL-RESPONSE; BCL-2; EXPRESSION; CELL-DEATH;
D O I
10.1007/s12253-013-9621-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives were to evaluate the relevance of proliferating fraction (Ki-67) along with apoptotic index (AI) which denoted growth index (Ki-67/AI ratio, GI) to predict pathological response to preoperative chemotherapy, and the pattern of their modifications following chemotherapy in women with locally advanced breast cancer. Archival material of diagnostic biopsies and surgical specimens from 106 patients were examined. Response rate to chemotherapy in this group was 95 %, eight (8 %) patients achieved a pathological complete remission (pCR) and five (5 %) had a progressive/stable disease (PD/SD). The expression of Ki-67 and AI were assessed using immunohistochemistry and in situ DNA nick labeling assay respectively. Higher baseline level of Ki-67 and GI were associated with an improved pathological response (p = 0.0001 and p = 0.008), but the degree of correlation with GI was no greater than that with Ki-67 alone. Ki-67 below 1 % highly indicated a lack of tumor response. High AI which characterized the opposite chemo-sensitive tumors, pCR vs. PD/SD (p = 0.72) implied that treatment response was not influenced by the "presence" or "absence" of apoptosis. A significant decrease in Ki-67 (p < 0.001), AI (p = 0.035) and GI (p = 0.008) was found following chemotherapy, but percentage change in biomarker values revealed an increase in a number of cases. Higher initial Ki-67 and AI was associated with profound reduction of GI and raising value of GI after treatment, respectively. Such a variance of a given parameter elicited by chemotherapy may have various impact on disease outcome.
引用
收藏
页码:577 / 588
页数:12
相关论文
共 62 条
[1]  
Aas T, 2005, ONCOL REP, V13, P525
[2]   Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].
Albain, Kathy S. ;
Barlow, William E. ;
Shak, Steven ;
Hortobagyi, Gabriel N. ;
Livingston, Robert B. ;
Yeh, I-Tien ;
Ravdin, Peter ;
Bugarini, Roberto ;
Boehner, Frederick L. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Winer, Eric P. ;
Hudis, Clifford ;
Ingle, James N. ;
Perez, Edith A. ;
Pritchard, Kathleen I. ;
Shepherd, Lois ;
Gralow, Julie R. ;
Yoshizawa, Carl ;
Allred, D. Craig ;
Osborne, C. Kent ;
Hayes, Daniel F. .
LANCET ONCOLOGY, 2010, 11 (01) :55-65
[3]   Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer [J].
Archer, CD ;
Parton, M ;
Smith, IE ;
Ellis, PA ;
Salter, J ;
Ashley, S ;
Gui, G ;
Sacks, N ;
Ebbs, SR ;
Allum, W ;
Nasiri, N ;
Dowsett, M .
BRITISH JOURNAL OF CANCER, 2003, 89 (06) :1035-1041
[4]   Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer [J].
Arpino, G ;
Ciocca, DR ;
Weiss, H ;
Allred, DC ;
Daguerre, P ;
Vargas-Roig, L ;
Leuzzi, M ;
Gago, F ;
Elledge, R ;
Mohsin, SK .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 92 (01) :69-75
[5]   Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer [J].
Assersohn, L ;
Salter, J ;
Powles, TJ ;
A'hern, R ;
Makris, A ;
Gregory, RK ;
Chang, J ;
Dowsett, M .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (02) :113-123
[6]  
Bertheau P, 2005, ONCOL REP, V14, P513
[7]  
Bloom HJG, 1957, BRIT J CANCER, V11, P337
[8]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[9]   Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer [J].
Bottini, A ;
Berruti, A ;
Bersiga, A ;
Brizzi, MP ;
Bruzzi, P ;
Aguggini, S ;
Brunelli, A ;
Bolsi, A ;
Bolsi, G ;
Allevi, G ;
Generali, D ;
Betri, E ;
Bertoli, G ;
Alquati, P ;
Dogliotti, L .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1106-1112
[10]   Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer - The role of anthrocycline dose intensity [J].
Bozzetti, C ;
Musolino, A ;
Camisa, R ;
Bisagni, G ;
Flora, M ;
Bassano, C ;
Martella, E ;
Lagrasta, C ;
Nizzoli, R ;
Personeni, N ;
Leonardi, F ;
Cocconi, G ;
Ardizzoni, A .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (02) :171-177